€575,000 - Asking Price|2 Bedrooms, 71 sqm approx
This is an amazing opportunity to acquire a spacious and bright 2-bedroom apartment overlooking Grand Canal Dock, in the heart of Dublin's most vibrant and fashionable district. Positioned on the fourth floor of this ever-popular development No.16 offers the pinnacle in urban living. The property enjoys spectacular views of the Grand Canal Basin, Dublin 2’s cityscape, and beyond.
In excellent decorative order throughout, this light filled, owner-occupied apartment comes to the market in turn key condition. The well-proportioned accommodation comprises; a bright hallway with ample storage, spacious dual aspect living/dining room with access to the balcony, a modernized kitchen lies just off this, a generous sized main bathroom and large guest bedroom with fitted wardrobes. The master bedroom includes fitted wardrobes and a fully tiled en-suite. Undoubtedly a stand out feature is the large balcony, accessible from the living room & bedrooms, that overlooks the water and is completely private. With floor to ceiling windows throughout the apartment completely unobstructed views of the water can be equally enjoyed from inside the apartment. One secure underground parking space is also included.
Located in the most sought-after city district in Dublin, the property is set within a leisurely walking distance to the City Centre, Ballsbridge, IFSC and Sandymount beach. Served by an extensive public transport network which includes the Grand Canal Dock Station for DART and inter-city trains, Dublin Bus services with a Dublin Bike station just outside your door . The area is well served by all social and essential amenities including many delightful establishments such as Bord Gáis Energy Theatre, the 3Arena, Aviva Stadium, Donnybrook Fair, Fresh, Milano, Herbstreet, CHQ Building, Sprout & Co, Charlotte Quay & The Marker Hotel. This prime location offers favorable yields with Grand Canal Dock is home to a broad range of prestigious employers including Facebook, Google, HSBC, Accenture, Pfizer and more.